Cargando…
Integrated multi-omics analyses reveal effects of empagliflozin on intestinal homeostasis in high-fat-diet mice
Obesity has become a global epidemic, associated with several chronic complications. The intestinal microbiome is a critical regulator of metabolic homeostasis and obesity. Empagliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor, has putative anti-obesity effects. In this study, we used mu...
Autores principales: | Shi, Junfeng, Qiu, Hongyan, Xu, Qian, Ma, Yuting, Ye, Tongtong, Kuang, Zengguang, Qu, Na, Kan, Chengxia, Hou, Ningning, Han, Fang, Sun, Xiaodong |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9830204/ https://www.ncbi.nlm.nih.gov/pubmed/36636340 http://dx.doi.org/10.1016/j.isci.2022.105816 |
Ejemplares similares
-
Empagliflozin Attenuates Obesity-Related Kidney Dysfunction and NLRP3 Inflammasome Activity Through the HO-1–Adiponectin Axis
por: Ye, Tongtong, et al.
Publicado: (2022) -
Transcriptomic Analysis Reveals the Protective Effects of Empagliflozin on Lipid Metabolism in Nonalcoholic Fatty Liver Disease
por: Ma, Yuting, et al.
Publicado: (2021) -
Empagliflozin activates Sestrin2-mediated AMPK/mTOR pathway and ameliorates lipid accumulation in obesity-related nonalcoholic fatty liver disease
por: Ma, Yuting, et al.
Publicado: (2022) -
Irisin protects against obesity-related chronic kidney disease by regulating perirenal adipose tissue function in obese mice
por: Han, Fang, et al.
Publicado: (2022) -
Effect of high-fat diet and empagliflozin on cardiac proteins in mice
por: Pan, Xiaoyu, et al.
Publicado: (2022)